Sook-Yeon Lee

Sook-Yeon Lee is a prominent inventor based in Seoul, South Korea. She has made significant contributions to the field of cancer therapy through her innovative research and development of antibodies targeting HER2. Her work aims to improve treatment options for patients suffering from cancers, particularly breast and stomach cancers.

Latest Patents

Sook-Yeon Lee holds a patent for an antibody specifically binding to HER2. This invention relates to HER2 (Human Epidermal Growth Factor Receptor 2) antibodies designed to prevent or treat cancers. The antibodies bind specifically to HER2 over-expressed in cancer cells, particularly in breast and stomach cancer cells. The unique CDR sequences of these antibodies exhibit low similarity to those of publicly known HER2 antibodies, highlighting their distinctiveness. The antibodies, when used in combination with trastuzumab, demonstrate significantly enhanced cytotoxicity, making them highly effective in cancer therapy.

Career Highlights

Throughout her career, Sook-Yeon Lee has focused on developing innovative solutions for cancer treatment. Her research has led to advancements in the understanding of HER2 and its role in cancer progression. She is dedicated to improving patient outcomes through her groundbreaking work in antibody development.

Collaborations

Sook-Yeon Lee collaborates with esteemed colleagues, including Jong-Seo Lee and Kyu-Tae Kim. These partnerships enhance her research efforts and contribute to the advancement of cancer therapies.

Conclusion

Sook-Yeon Lee's contributions to the field of cancer therapy through her innovative antibody research exemplify her commitment to improving treatment options for patients. Her work continues to pave the way for advancements in cancer treatment and patient care.

Profile summary based on public USPTO records.